Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Sep;41(3):513-528.
doi: 10.1016/j.ccm.2020.06.003.

Pulmonary Rehabilitation

Jean Bourbeau  1 , Sebastien Gagnon  2 , Bryan Ross  2
Affiliations
Review

Pulmonary Rehabilitation

Jean Bourbeau et al. Clin Chest Med. 2020 Sep.

Abstract

Pulmonary rehabilitation (PR) is an essential intervention in the management of patients with chronic obstructive pulmonary disease. To guide health care professionals in the implementation and evaluation of a PR program, this article discusses the current key concepts regarding exercise testing, prescription, and training, as well as self-management intervention as essential parts of PR and post-rehabilitation maintenance. Moreover, new approaches (alternative forms of organization and delivery, tele-rehabilitation, exercise adjuncts) and unique and challenging situations (patients experiencing acute exacerbations, advanced disease) are thoroughly reviewed. Finally, validated point-of-care resources and online tools are provided.

Keywords: COPD; Exacerbation; Exercise training; Physical activity; Physical and rehabilitation medicine; Physical education and training; Self-management; Symptom flare up.

PubMed Disclaimer

Conflict of interest statement

Disclosure J. Bourbeau reports no funding pertaining to this article. He reports grants from CIHR and Canadian Respiratory Research Network (CRRN), Foundation of the McGill University Health Center, Aerocrine, AstraZeneca, Boehringer Ingelheim, Grifols, GlaxoSmithKline, Novartis, and Trudell; personal conference and advisory board fees from Canadian Thoracic Society, CHEST, Astra Zeneca, Boehringer Ingelheim, Grifols, GlaxoSmithKline, Novartis, and Trudell. S. Gagnon and B. Ross do not report any commercial, financial, or other conflicts of interest.

MeSH terms